Bellerophon Therapeutics | 15-12G:终止注册
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics | SCHEDULE 13G:其他
Bellerophon Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Perceptive Advisors LLC(0.0%),Joseph Edelman(0.0%)等
Bellerophon Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-TANG CAPITAL PARTNERS, LP(0.0%),Tang Capital Management, LLC(0.0%)等
Bellerophon Therapeutics | DEFA14A:其他
Bellerophon Therapeutics | DEFA14A:其他
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics | SCHEDULE 13G:其他
Bellerophon Therapeutics | SC 13G:超过5%持股股东披露文件-507 Summit LLC(8.4%),Lepercq Capital Management LLC(8.4%)等
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics | DEFA14A:其他
Bellerophon Therapeutics | 25-NSE:由交易所申报的注销已到期、已赎回、已兑付证券的通知
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics | 8-K:重大事件
Bellerophon Therapeutics:2023财年三季报
Bellerophon Therapeutics | DEF 14A:股东委托书决议
Bellerophon Therapeutics | PRE 14A:并购重组委托声明
Bellerophon Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Theodore Wang(0.5%),Puissance Life Science Opportunities Fund VI(0%)等
暂无数据